1. Figure S1. (a) Western blot of purified recombinant truncated His-hTAF9 1-140 and His-Fiber as detected by anti-His antibody. His-hTAF9 1-140 was verified by anti-TAF9 antibody. (b) ELISA showed direct binding between biotinylated p53 peptide (with putative TAF9 binding motif) and purified recombinant His-hTAF9 1-140, but not the recombinant His-Fiber protein. (c) Gli dependent transcription activity was significantly inhibited by knocking down TAF9 expression with TAF9 shRNA in NSCLC cell line A549. His-Fiber His-TAF9 WB: anti-His anti-TAF9 His-TAF9 His-Fiber a Ctrl shRNA TAF9 shRNA Gli1 + TAF9Gli2 + TAF9 Gli BS-luc activity (%) biotin-p53 peptide c b

2. Figure S2. Effect of FN1-8 on other transcription factors. (a) CREB and HIF binding sites-luciferase reporter activities in stable cell lines 293 and NIH3T3 (Panomics) were not affected by FN1-8 (10 and 20 µM, 1 day). (b) The SOCS3 promoter (with STAT3 binding sites, (He, et al. BBRC 2003)) activity in A549 cells was not affected by by FN1-8 (20 µM, 1 day). All the measured luciferase activities were normalized to pRL ‑ TK vector (Promega) activity. Results are means + S.D. DMSO10µM FN1-820µM FN1-8 a b

3. b Live cells (%) DMSO10 µM FN1-830 µM FN1-8 Normal muscle cellsNormal renal cells c Figure S3. Effect of FN1-8 on survival in several types of human normal cells. (a) Normal lung cells and (b) Normal muscle and renal cells were treated with different doses of FN1-8 for 4 days and then analyzed by flow cytometry. (c) Normal skin fibroblast were treated with different doses of FN1-8 and analyzed by MTS assay (time course). All results are mean values ± S.D. (error bars). DMSO 10 µM FN1-8 20 µM FN1-8 Normal skin fibroblast 123456 Days Live cells (%) Normal lung cells FN1-8 a

4. DMSO FN1-8 Kidney cortexKidney medulla Lung Spleen Liver Small intestineColon Ear c Figure S4. Pharmacokinetic (PK) and toxicity studies of FN1-8 in mice. (a) PK study of FN1-8 in mice (n=3) by i.p. injection (30 mg/kg). Results are means±SD. (b), (c) and (d) are toxicity analyses of FN1-8 in mice harboring H460 tumors of the efficacy study described in Figure 6. Body weights of mice were monitored during the period of drug administration (b). Hematoxylin and eosin (H&E) staining of organs (c). Leukocytes (WBC: white blood cell, NE: neutrophil, LY: lymphocyte, MO: monocyte, EO: eosinophil, BA: basophil) from animals were collected and counted through a blood cell counter (d). Normal ranges (x10 3 counts/ul) for the leukocyte population are: WBC: 1.8-10.7; NE: 0.1- 2.4; LY: 0.9-9.3; MO: 0-0.4; EO: 0-0.2; BA: 0-0.2. Leukocyte population Counts (10 3 /μl) FN1-8 Vehicle d a FN1-8 Vehicle b i.p. injection Concentration (ng/ml) Time (hrs)

5. Table S2. Primer sequences for semi-quantitative RT-PCR GenePrimer SequencesSize (bp) Gli1F: 5’-TACTCACGCCTCGAAAACCT-3’ R: 5’-GTCTGCTTTCCTCCCTGATG-3’ 340 Gli2F: 5’-CACCAACCAGAACAAGCAGA-3’ R: 5’-ACCTCAGCCTCCTGCTTACA-3’ 195 ShhF: 5’-CAGTGGCCAGGAGTGAAACT-3’ R: 5’-CCAGGAAAGTGAGGAAGTCG-3’ 380 Ptch1F: 5’-CGCCTATGCCTGTCTAACCATGC-3’ R: 5’-TAAATCCATGCTGAGAATTGCA-3’ 448 GAPDHF: 5'-ATGGGGAAGGTGAAGGTCGG-3' R: 5'-GACGGTGCCATGGAATTTGC-3' 180 Table S1. Peptide sequences for ELISA Protein MotifPeptide Sequences Gli1-TAF9bd(NH2)-LDSLDLDNTQLDFVAILDEPQG-(COOH) Gli2-TAF9bd(NH2)-VDSQLLEAPQIDFDAIMDDGDH-(COOH) Mutant Gli2-TAF9bd(NH2)-VDSQLLEAPQIDADAIADDGDH-(COOH) p53-TAF9bd(NH2)-DPSVEPPLSQETFSDLWKLLPE-(COOH)